Genmab A/S (NASDAQ:GMAB) Shares Gap Up to $27.72

Genmab A/S (NASDAQ:GMAB) gapped up prior to trading on Friday . The stock had previously closed at $27.72, but opened at $29.73. Genmab A/S shares last traded at $29.50, with a volume of 205,982 shares.

Wall Street Analysts Forecast Growth

GMAB has been the subject of several research reports. Truist Financial reaffirmed a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research note on Tuesday, March 26th. Citigroup lowered Genmab A/S from a “neutral” rating to a “sell” rating in a report on Monday, January 22nd. BMO Capital Markets raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and increased their price target for the company from $46.00 to $48.00 in a report on Friday, February 23rd. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research note on Tuesday, April 30th. Finally, Morgan Stanley reiterated an “underweight” rating on shares of Genmab A/S in a research note on Tuesday, March 26th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $48.50.

Genmab A/S Trading Up 7.2 %

The stock’s 50-day moving average price is $29.39 and its two-hundred day moving average price is $29.90. The stock has a market capitalization of $19.65 billion, a P/E ratio of 24.77, a P/E/G ratio of 1.99 and a beta of 1.00.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Wednesday, February 14th. The company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.02. Genmab A/S had a return on equity of 19.20% and a net margin of 30.74%. The business had revenue of $675.29 million for the quarter, compared to analysts’ expectations of $678.14 million. On average, equities research analysts predict that Genmab A/S will post 1.06 earnings per share for the current year.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds have recently added to or reduced their stakes in the company. Headlands Technologies LLC purchased a new stake in Genmab A/S during the third quarter valued at about $27,000. Pinnacle Bancorp Inc. grew its position in Genmab A/S by 315.8% during the 4th quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company’s stock worth $27,000 after acquiring an additional 638 shares during the last quarter. GAMMA Investing LLC increased its stake in Genmab A/S by 194.0% in the 1st quarter. GAMMA Investing LLC now owns 1,135 shares of the company’s stock worth $34,000 after purchasing an additional 749 shares during the period. NBC Securities Inc. bought a new stake in Genmab A/S in the third quarter valued at approximately $37,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Genmab A/S by 86.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,075 shares of the company’s stock valued at $38,000 after purchasing an additional 498 shares during the period. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.